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Abstract: Neuropsychiatric symptoms (NPS) are core features of Alzheimer’s disease and 
related dementias. On one hand, behavioral symptoms in patients with mild cognitive impair-
ment (MCI) can indicate an increased risk of progressing to dementia. On the other hand, 
mild behavioral impairment (MBI) in patients who usually have normal cognition indicates an 
increased risk of developing dementia. Whatever the cause, all dementias carry a high rate of 
NPI. These symptoms can be observed at any stage of the disease, may fluctuate over its course, 
are a leading cause of stress and overload for caregivers, and increase rates of hospitalization and 
early institutionalization for patients with dementia. The clinician should be able to promptly 
recognize NPI through the use of instruments capable of measuring their frequency and sever-
ity to support diagnosis, and to help monitor the treatment of behavioral symptoms. The aims 
of this review are to describe and update the construct ‘MBI’ and to revise the reported NPS 
related to prodromal stages of dementia (MCI and MBI) and dementia stages of Alzheimer’s 
disease and frontotemporal lobar degeneration.
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Introduction
Over the last several years, awareness of the importance of neuropsychiatric symp-
toms (NPS) in dementia has been increasing, given their universal occurrence 
over the course of dementia and their association with caregiver burden and early 
institutionalization.1,2
Whereas dementia is still defined as a cognitive disorder, NPS are now regarded 
as an intrinsic aspect of dementia, and that their underlying causes are usually neu-
rodegenerative processes.1,2
NPS are almost always present in the dementia patient, and they are common hall-
marks of all types of dementia, independent of etiology. Patients diagnosed with mild 
cognitive impairment (MCI) present with a higher rate of NPS than healthy people.3,4 
Moreover, in the MCI population, the risk of developing dementia is high when NPS 
are present.5,6 Patients with a diagnosis of mild behavioral impairment (MBI)7 show 
a notably increased risk of progression to degenerative dementia, even in those with 
normal cognition.7
The presence of NPS in dementia patients is associated with high caregiver burden,8 
poor prognosis, and higher rates of institutionalization and drug therapy; all of which 
contribute to an increased social and economic impact in people with dementia and 
MCI.9 In order to be able to control these variables, NPS should be rapidly recognized 
and treated.
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The aims of this review are to describe and update the 
MBI construct7 and to revise NPS as related to prodromal 
stages of dementia (MCI and MBI), and dementia stages 
of Alzheimer’s disease (AD) and frontotemporal lobar 
degeneration.
Search strategy and selection 
criteria
We searched MEDLINE, LILACS, and AgeLine databases 
from 1976 to the present, using the keywords “neuropsychi-
atric symptoms”, “behavioral and psychological symptoms”, 
“dementia”, “mild cognitive impairment”, “mild behavioral 
impairment”, and “treatment”. We focused on empirical stud-
ies, meta-analyses, and authoritative reviews published since 
1997, as this is when most of the progress towards under-
standing dementia-related NPS has occurred. We selected 
articles published in the English language.
We found 167 review articles in PubMed, between 1976 
and 2012, with the keywords “neuropsychiatric symptoms 
in dementia”. We analyzed 22 empirical studies related to 
NPS in MCI, and 30 papers related to dementia (reviews and 
empirical studies). We searched for the terms “behavioral 
symptoms in dementia”, “treatment”, “neuropsychiatric 
symptoms in dementia”, “treatment”, and selected 52 papers, 
including reviews, empirical studies, and meta-analyses; 
20 of these were analyzed. Finally, we analyzed five papers 
found using the terms “antipsychotics” and “dementia”.
Neuropsychiatric symptoms (NPS)
“Neuropsychiatric symptoms”, as they are most commonly 
referred to in the USA (also known as “behavioral and psy-
chological symptoms of dementia” [BPSD] according to 
the International Psychogeriatric Association),10 represent a 
heterogeneous group of non-cognitive symptoms and behav-
iors occurring in subjects with dementia. BPSD constitute 
a major component of the dementia syndrome, irrespective 
of its subtype. They are as clinically relevant as cognitive 
symptoms, as they strongly correlate with the degree of 
functional and cognitive impairment.11
Common NPS can include agitation, anxiety, irritability, 
illusion and delusions, apathy, depression, disinhibition, 
aberrant motor and obsessive–compulsive behaviors, and 
sleep disorders, among others. These manifestations can be 
present at any stage of dementia and non-dementia–cognitive 
impairment.
The pathogenesis of NPS has not been clearly delineated 
but it is probably the result of a complex interplay of psycho-
logical, social, and biological factors. Recent studies have 
emphasized the role of neurochemical, neuropathological, 
and genetic factors underlying the clinical manifestations 
of BPSD.11
Despite being almost universally present during the 
course of dementia, BPSD have not been included in the 
defining criteria for dementia in the Diagnostic and Statistical 
Manual of Mental Disorders, fourth edition, text revision 
(DSM-IV-TR)12 or International Statistical Classification of 
Diseases and Related Health Problems, tenth revision (ICD-
10)13 classification systems. The core features of dementia 
according to these classifications consist of a gradual onset 
of multiple cognitive deficits (involving memory and at least 
one additional cognitive domain) not occurring exclusively 
during delirium and representing a decline from a previous 
level of functioning.12
However, in the DSM-5,14 NPS are considered in 
some dementias such as frontotemporal dementia (FTD) 
 (Behavioral variant Frontotemporal Neurocognitive  Disorder, 
DSM-5), Lewy Body Dementia  (Neurocognitive Disorder 
due to Lewy Body Dementia, DSM-5), and  prodromal stages 
of dementia.
Validated scales for NPS assessment
Validated instruments, both general scales and focused scales, 
can be used to determine the presence, intensity, or frequency 
of NPS in patients with MCI and dementia. General scales 
allow a broad spectrum of NPS to be assessed, while focused 
scales are used to assess one or more behavioral symptoms 
(for example, scales for depression or agitation).
General scales are used to conduct multidimensional 
examinations, and include the Behavioral Pathology in 
Alzheimer’s Disease Rating Scale (BEHAVE-AD),15 the 
Neurobehavioral Rating Scale,16 the Behavioral Rating Scale 
for Dementia,17 and the Neuropsychiatric Inventory (NPI).18 
The NPI is the most widely used scale to measure NPS 
associated with cognitive disorders. It is a fully structured 
interview, which obtains data from an informant, usually the 
patient’s caregiver. Recently, the NPI – Clinician (NPI-C) was 
developed.19 The revised NPI-C can be used to assess single 
or multiple domains.20 Unlike the NPI, each domain and 
potentially each sub-question within a domain, can be rated 
on the NPI-C. Caregivers and patients rate the frequency, 
severity, and distress of each item, and then the clinician 
provides an overall rating based on interviews and additional 
chart information, which brings additional strength to the 
measure compared with the original scale.
The NPI-C was field tested in an international valida-
tion study and compared with focused scales to determine 
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convergent validity. It was trimmed to 142 items (61 more 
than the NPI) and has been translated to several European 
languages.20
Focused scales are instruments that are used to conduct 
uni-dimensional evaluations, and include the Hamilton 
Depression Rating Scale,21 the Cornell Scale for  Depression 
in Dementia,22 the Geriatric Depression Scale,23 or the 
Cohen–Mansfield Agitation Inventory.24
NPS in pre-dementia  
stages of Alzheimer’s disease  
and frontotemporal dementia
Mild behavioral impairment (MBi)
Although NPS are common in dementia, they have received 
less attention in prodromal dementia states. In  addition, not 
all prodromal states involve prominent cognitive  impairment. 
Many patients develop NPS as the first indicator of impend-
ing dementia. This is most common in patients with FTD, but 
is also the case in patients with AD. Taragano and Allegri25 
reported that, in 50% of a series of dementia consulting 
patients, NPS were the first indication of change, before the 
occurrence of cognitive symptoms. As a result they proposed 
the syndrome ‘mild behavioral impairment’, referring to a 
late-life syndrome with prominent psychiatric and related 
behavioral symptoms in the absence of prominent cognitive 
symptoms, which may also be a dementia prodrome.
In a recent study, Taragano et al7 followed a consecutive 
series of 358 patients for up to 5 years. The objective was 
to compare MCI and MBI patients and estimate the risk of 
dementia development in both groups. MBI was defined as 
a behavioral disturbance not meeting DSM-IV or National 
Institute of Neurological and Communicative Disorders 
and Stroke/Alzheimer’s Disease and Related Disorders 
Association criteria for dementia, psychosis, or other major 
psychiatric condition, and also not meeting criteria for MCI 
of any type. It was operationalized following the inclusion 
criteria shown in Table 1.
Examples of major persistent changes in patient behavior 
that can lead to a diagnosis of MBI are as follows: agita-
tion, anxiety symptoms, apathy, aspontaneity, delusion 
symptoms, depressive symptoms, disinhibition, emotional 
lability, euphoria, impulsivity, indifference, irritability, lack 
of empathy, loss of insight, loss of personal hygiene, loss of 
social tact, oral/dietary changes, perseverant behavior, and 
sleeping disorders.
Results of this research showed that NPS were consis-
tently and robustly associated with faster time to dementia 
conversion across both groups. Although this has been previ-
ously reported, this study emphasized the importance of NPS, 
even in the absence of cognitive symptoms, as the MBI group 
without cognitive complaints converted to dementia faster 
than the MCI group without psychiatric complaints. Rates 
of dementia conversion in the MBI group with cognitive 
complaints were comparable to those in the MCI group with 
NPS, suggesting that these two groups could probably be con-
sidered as one. Finally, the presence of MBI was associated 
with clinical and neuroimaging evidence of abnormalities 
in the frontal regions of the brain, and with a greater risk of 
conversion to FTD than to AD. Hence, MBI, specifically in 
the absence of cognitive symptoms, probably represents an 
FTD prodrome in at least half of the cases in this study.
In a post hoc analysis of the study, the authors did not 
find any relationship between depression and a greater risk 
of dementia; therefore, in a new second cohort of patients 
(2007–2012) who were followed for up to 5 years, one focus 
was to study the relationship between cognitive symptoms in 
depression and the risk of dementia. New data emerged: the 
risk of dementia was higher only when the depressive syn-
drome was present with cognitive impairment of the cortical 
and not the subcortical type. The cortical cognitive profile 
in depression, usually uncommon, refers mainly to verbal 
learning memory or naming or semantic fluency impairment, 
while the most common subcortical profile refers mainly to 
attention or executive impairments. Furthermore, the great 
majority of depressed patients who showed no improvement 
in cognitive cortical impairment after remission of depres-
sion had an abnormal cerebrospinal fluid level of Abeta1-42 
protein confirmed by lumbar puncture.
Other important findings in this new second cohort  concern 
the presence of a control group (n = 165)  comprising psychi-
atric patients with neither MCI nor MBI. More patients in the 
MBI group converted to dementia (67/96) than in the MCI 
(36/87) and control (23/165) groups, showing a statistically 
significant difference χ2 = 83.3, df = 2; P , 0.001. Even when 
compared with subgroups of anxiety, depression, or  psychosis, 
the difference remained significant χ2 = 132; df = 15; P , 0.001 
(Taragano et al, unpublished data).
Table 1 Mild behavioral impairment inclusion criteria7
a. Presence of a major change in patient behavior
b. Change occurring later in life (.60) that is persistent (.6 months)
c. No complaint of cognitive impairment by patient/informant
d. Normal occupational and social functioning
e. Normal activities of daily living
f. Absence of dementia
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These findings have implications for the early detec-
tion, prevention, and treatment of patients with dementia 
in late life by focusing on the emergence of new behavioral 
symptoms.7
Mild cognitive impairment (MCi)
MCI represents an intermediate state of cognitive function 
between the changes observed in aging and the dementia 
diagnosis. It is currently defined as a syndrome with impair-
ment of memory or another cognitive domain that does not 
interfere substantially with personal autonomy.26 The National 
Institute on Aging (http://www.nia.nih.gov) and the Alzheim-
er’s Association (http://www.alz.org) developed criteria for 
the symptomatic pre-dementia phase of AD, referred to here 
as ‘MCI due to AD’. The workgroup developed the following 
two sets of criteria: (1) core clinical criteria that could be used 
by healthcare providers without access to advanced imaging 
techniques or cerebrospinal fluid analysis, and (2) research 
criteria that could be used in clinical research settings, includ-
ing clinical trials. The second set of criteria incorporate the 
use of biomarkers based on imaging and cerebrospinal fluid 
measures. The final set of criteria for MCI due to AD has four 
levels of certainty, depending on the presence and nature of 
the biomarker findings.27 Moreover, in the DSM-5, MCI is 
classified as an entity: mild neurocognitive disorder.14
Concomitant to the description of MCI, NPS were better 
recognized.28,29 It is important to detect NPS because (1) they 
assist in the early diagnosis of conversion to dementia; (2) they 
are markers for increased risk of progression to dementia; and 
(3) therapeutic management of behavioral symptoms may 
provide an opportunity for successful outcome.28,29
NPS are common in MCI patients; however, their fre-
quency is modified when considering community or tertiary 
healthcare centers. A review on behavioral symptoms in 
MCI showed that depression, apathy, and anxiety were the 
most frequent.30
NPS in MCi
Various empirical studies have been developed to investigate 
NPS in MCI. Table 2 summarizes data from the last 3 years.
Depression is the most studied symptom in MCI and 
dementia. The most frequent depressive symptoms observed 
in these patients are irritability, impairment of attention 
and concentration, paranoid and obsessive thoughts, lack 
of insight, psychomotor retardation, and weight loss. The 
prevalence of depressive symptoms may be as high as 45%.31 
In a large prospective study, the possibility of converting to 
dementia during follow-up was 2.6 times greater if depression 
was present in MCI subjects at baseline.6 Another longitudi-
nal study showed an increased presence of depression, from 
baseline status, in patients who developed cognitive impair-
ment and dementia versus the control population with stable 
cognition and healthy patients,32 concluding that depressive 
symptoms are associated with cognitive decline. However, 
the importance of depression as a risk factor for developing 
dementia could not be demonstrated in other studies.5,33
Butters et al34 propose that depression alters an indi-
vidual’s risk of cognitive dysfunction, shortening the latent 
period between the development of AD neuropathology and 
the onset of clinical dementia, thus increasing the incidence 
and prevalence of AD among older adults with depression.
Apathy (lack of motivation, diminished goal-directed 
behavior, and decreased emotional engagement) is a prevalent 
behavioral manifestation in MCI patients. Community and 
tertiary center studies30 have found that approximately one-
third of patients with a diagnosis of MCI suffers apathy.
The presence of apathy symptoms increases the likelihood 
of developing AD.35 In a European study,5 a diagnosis of apa-
thy in amnestic-MCI (a-MCI) patients represented a 7-fold 
increased risk of developing AD. Similar to that observed in 
AD, the prevalence of apathy in MCI patients increases in 
relation to the decline of cognitive function.36 Apathy was 
observed more frequently in multiple-domain MCI than in 
a-MCI, mainly in relation to executive dysfunction. In clinical 
practice, the presence of apathy in an MCI context allows the 
identification of people with potential AD.36
In a study about neuropsychiatric predictors of progression 
from a-MCI to AD, the presence of apathy, but not depression, 
predicted patients with a-MCI who progressed to AD. The 
authors found that apathy had an important impact on a-MCI 
and should be considered a mixed cognitive/psychiatric dis-
turbance related to ongoing AD neurodegeneration.
The third most common NPS is anxiety. The literature 
on the prevalence of anxiety is conflicting, perhaps due 
to differences in diagnostic criteria. Anxiety is defined as 
an excessive apprehension and feeling of foreboding,36 
and its diagnostic frequency varies from 10%28 to 45%.31 
Demey et al4 found that 37% of MCI patients had anxiety 
versus 5% of a control group. In a study with 3 years of 
follow-up, people with a diagnosis of MCI and the presence 
of anxiety symptoms had a higher risk of progressing to AD 
than individuals with MCI without anxiety.33
A recent study of NPS in MCI subtypes,37 including 
1,779 participants, concluded that, while there were few 
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Table 2 Neuropsychiatric symptoms in mild cognitive impairment. Data reviewed from 2010 to 2012
Study Patients Objective Conclusions
Somme et al87 132 To identify NPS that predict the progression  
from a-MCi to dementia using an  
easy-to-administer screening tool for NPS
Faster progression to dementia was observed in  
patients with either night-time behavioral disturbance,  
apathy, or anxiety as well as in those with a higher  
number of items affected
Peters et al88 230 To examine the association of NPS severity  
with risk of transition to all-cause dementia,  
AD and vaD
The presence of at least one NPS was a risk factor  
for all-cause dementia, as was the presence of NPS  
with mild severity. Night-time behaviors were a risk  
factor for all-cause dementia and of AD, whereas  
hallucinations were a risk factor for vaD
Shahnawaz et al89 767 To study the prevalence and characteristics  
of depressive symptoms in MCi
individuals with MCi symptoms, when compared  
especially with a-MCi, express more depressive  
symptoms than cognitively intact individuals. 
These findings highlight the importance of assessing  
and treating depressive symptoms in MCi
Richard et al90 397 To investigate if apathy predicts the  
progression from MCi to AD
Symptoms of apathy, but not of depressive affect,  
increase the risk of progression from MCi to AD.  
Apathy in the context of symptoms of depressive affect 
does not increase this risk. Symptoms of apathy and  
depression have differential effects on cognitive decline
Lee et al91 243 To examine the neuroanatomical changes  
associated with depressive symptoms in MCi
Depressive symptoms were associated with greater  
atrophy in AD-affected regions, increased cognitive  
decline, and higher rates of conversion to AD.  
Depression in individuals with MCi may be associated  
with underlying neuropathological changes, including  
prodromal AD, and may be a potentially useful clinical  
marker in identifying MCi patients who are most likely  
to progress to AD
Gallagher et al92 161 To determine whether NPS track existing  
measures of declining cognitive and functional  
status or may be considered distinct and  
sensitive biomarkers of evolving Alzheimer’s  
pathology
NPS and, in particular, anxiety symptoms are common  
in patients with MCi. in this sample, anxiety for  
upcoming events and purposeless activity frequently  
co-occurred and were significant clinical predictors  
of earlier conversion to AD. However, these findings  
were not independent of cognitive status at baseline  
and therefore may be markers of severity rather than  
independent predictors of disease progression
Chan et al93 321 To explore the association between NPS and  
risk of cognitive decline in Chinese older  
persons residing in the community
Depression in non-demented older patients may  
represent an independent dimension reflecting early  
neuronal degeneration. Further studies should be  
conducted to assess whether effective management  
of NPS exerts beneficial effects on cognitive function
Ryu et al94 220 To determine the persistence of NPS over 6  
months in participants with MCi
NPS were highly persistent overall in older people  
with MCi. Persistence was predicted by having more  
severe symptoms at baseline. Clinically significant  
levels of NPS were associated with decreased quality  
of life. we conclude that clinicians should be aware  
that NPS symptoms in MCi usually persist
Palmer et al5 131 To evaluate whether depression or apathy  
in patients with a-MCi increases the risk of  
progressing to AD
Apathy, but not depression, predicts which patients  
with a-MCi will progress to AD. Thus, apathy has an  
important impact on a-MCi and should be considered  
a mixed cognitive/psychiatric disturbance related to  
ongoing AD neurodegeneration
Ramarkers et al95 263 To investigate the predictive accuracy of  
affective symptoms for AD during a follow-up  
study in subjects with MCi, and whether the  
predictive accuracy was modified by age, the  
presence of a-MCi or the length of follow-up
Affective symptoms are associated with a decreased  
risk for AD. The risk may be dependent on MCi  
subtype or length of follow-up, but it does not  
depend on age
Abbreviations: AD, Alzheimer’s disease; a-MCi, amnestic mild cognitive impairment; NPS, neuropsychiatric symptoms; vaD, vascular dementia.
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associations between a-MCI and NPS, the presence of execu-
tive dysfunction in MCI was associated with greater severity 
of symptoms, and specifically with depression (evidenced by 
the Geriatric Depression Scale [GDS] score)23 and anxiety.37
Other symptoms, such as agitation (physical or verbal 
outbursts, general emotional distress, restlessness, pacing, 
shredding paper or tissues, yelling) and irritability (abnor-
mally excitable or sensitive to stimulation, readily excited to 
impatience or anger), show lower prevalence in MCI patients 
compared with depression, apathy, and anxiety. Irritability 
was observed in almost 20% of MCI patients in a large 
community-based study.3 The presence of irritability reached 
55% in a tertiary referral center-based study.4 Agitation 
symptoms have a lower prevalence but may be a marker of 
rapid cognitive impairment.30
Psychotic symptoms such as delusions, hallucinations, 
and illusions are rare in MCI patients.3 However, presence 
of these behavioral disturbances may reflect a major risk of 
developing dementia.
NPS in dementia stages  
of Alzheimer’s disease  
and frontotemporal dementia
Alzheimer’s disease
AD is a progressive neurodegenerative disease that is char-
acterized by impairment of cognitive and functional abili-
ties as well as by NPS. Cognitive impairment can include 
impairment of memory, visuospatial functions, language, 
and executive functions. In addition, NPS such as depression, 
apathy, and agitation seem to already be common in early 
stages of AD and can have an impact on the well-being of 
both patients and caregivers. Cognitive performance has been 
consistently associated with functional ability.38 In cogni-
tive impairment and dementia, both functional ability and 
behavior are significantly correlated with caregiver burden, 
although the strength of association is more than two times 
higher for behavioral changes.39
The neuroanatomic involvement of prefrontal subcortical 
limbic regions is an early feature of AD.40 Reflecting this is 
the early, often prodromal, appearance of neuropsychiatric 
and behavioral alterations that become more fulminate and 
problematic as AD progresses. Depression, anxiety, irrita-
bility, aggressiveness, apathy, euphoria, sleep and appetite 
disturbances, motor restlessness, hallucinations, delusions, 
and paranoia are typical features of fulminate AD.18 These 
features can be the presenting signs of an impending dementia 
years before cognitive decline becomes apparent, and are 
often the most difficult to deal with from the perspective of 
the caregiver, friends, family, and clinicians of individuals 
with AD at any stage.41
The NPS often get worse over the course of the disease 
and may fluctuate in presentation.36 Depression and apathy 
are the symptoms most frequently observed in the evolution 
of AD, and usually occur in early stages and in MCI.20
NPS in Alzheimer’s disease: 
neuroanatomical correlations
Most reports in the literature indicate that behavioral symp-
toms and cognition are not related,42,43 or that the relation-
ship is weak.44,45 There is also evidence that any change in 
behavioral symptoms is independent from changes occurring 
in cognitive measures.46 Instead, Harwood et al47 described 
a relationship between psychological and behavioral distur-
bances and Mini-Mental State Examination (MMSE) scores. 
Hallikainen et al found that NPS were not correlated with 
cognitive performance, showing that cognitive and behavioral 
disturbances are instead distinct entities in AD, at least in the 
mild stage of the disease.
Apathy is the most prevalent symptom in AD patients 
and its frequency increases in relation to illness progression. 
In early AD, 42% of patients showed apathy, increasing to 
90% in severe AD.48 This progression reflects the frontosub-
cortical dysfunction and the impairment in communication 
between the anterior cingulate cortex and other cortical 
areas that accompanies the progression of AD. Proposed 
diagnosis criteria for apathy in AD have recently been 
published.49
Post-mortem and in vivo studies suggest that AD is 
associated with a dysfunctional dopaminergic system, since 
reduced levels of dopamine and homovanillic acid, as well 
as altered dopamine-receptor density, have been described in 
discrete brain regions coinciding with the mesocorticolimbic 
pathway system,50 including atrophy,51 hypoperfusion, and 
hypometabolism in the anterior cingulate gyrus and orbito-
frontal areas.52 It is also possible that dysfunction in these 
areas underlies the reported relationship between increased 
changes in frontal white matter and apathy,53 together with 
disruption of deep white matter afferents and efferents to the 
basal ganglia and/or by decrement of metabolic activity in 
frontal subcortical regions.
Depression is another common symptom in AD, and 
proposed diagnosis criteria have just been published.54 
Mega et al48 found that the prevalence of depression 
was up to 60% in patients with advanced AD. A recent 
study of different subtypes of geriatric depression (major 
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depression disorder [MDD], dysthymia disorder [DD], 
subsyndromal depression disorder [SsD], and depression 
due to dementia of Alzheimer type [DdD]) reported that 
the DdD group presented moderate depressive symptoms 
associated with anxiety, similar to MDD group, they had 
the greatest cognitive impairment with a cortical profile, 
and showed the highest scores in daily life activities and 
caregiver burden scales than the other three groups (MDD, 
DD, SsD).55
Apathy and depression may occur together, but one 
must be differentiated from the other.35 Lyketsos and Lee56 
reported that the presence of depression was related to 
increased institutionalization, caregiver burden and caregiver 
depression.
In AD patients, psychotic symptoms can present with 
hallucinations and delusion and are associated with high 
caregiver burden.8 These symptoms are more frequently 
present in moderate and advanced stages, and could be drug 
or delirium induced.36 Hallucinations and delusions observed 
in AD have been proposed as a distinct syndrome, in order 
to differentiate it from other psychoses.57
In the Cardiovascular Health study,58 where the trajec-
tory of cognitive decline as a predictor of psychosis in early 
AD was evaluated, the working group found that individuals 
who ultimately develop psychosis have more rapid cogni-
tive deterioration during the earliest phases of AD than 
individuals with AD who do not develop psychosis. The 
genetic and other neurobiological factors leading to the 
expression of AD plus psychosis may exert their effects by 
acceleration of the neurodegenerative process. Two stud-
ies found an association between psychosis and increased 
severity of beta-amyloid senile plaques in the presubicu-
lum,59 and across cortical regions.60 Förstl et al61 reported 
changes in neuronal counts in the CA1 hippocampus and 
parahippocampal gyrus, while Zubenko et al59 described 
increased density of neurofibrillary tangles (NFTs) in the 
middle frontal cortex. Furthermore, Farber et al62 reported 
that AD patients with psychosis had a 2.3-fold greater 
density of neocortical NFTs than AD subjects devoid of 
psychotic symptoms.
Neuroimaging studies have similarly confirmed severe 
abnormalities in grey matter volume, cerebral blood flow, 
and metabolism in the above-mentioned cortical regions 
of AD subjects with psychotic symptoms.63 Anatomi-
cally, these changes partially coincide with cholinergic 
and dopaminergic pathways, supporting (together with 
neurochemical and pharmacological evidence) the role of 
acetylcholine and dopamine imbalance in the pathogenesis 
of AD psychosis.64 Psychosis has also been associated 
with the relative preservation of norepinephrine in the 
substantia nigra and a significant serotonin reduction in 
the presubiculum.65
Delusions have been associated with an increase in mus-
carinic receptors in the orbitofrontal cortex,20 as revealed in a 
study where fluorodeoxyglucose positron emission tomogra-
phy (PET) analysis correlated delusions with reduced glucose 
metabolism in the right frontal region.
Agitation and irritability are common behavioral 
symptoms. Recently, an Asian study found a prevalence of 
irritability/aggression greater than 70%.66 Altered glucose 
metabolism (measured by PET) has also been associated with 
anxiety, apathy, agitation, and disinhibition in AD involving 
multiple regions: anxiety was related to the bilateral ento-
rhinal cortex, anterior parahippocampal gyrus, left superior 
temporal gyrus, and insula; apathy was related to the bilateral 
anterior cingulated gyrus, medial orbitofrontal cortex, and 
medial thalamus; agitation/disinhibition was related to frontal 
and temporal lobes.20
The diagnosis of anosognosia is frequent in patients 
with mild AD but not in those with MCI. In the latter 
case, a true anosognosia was not able to be identified, 
but rather only a decreased awareness of illness.67 Fur-
thermore, reduced awareness of cognitive difficulties is 
linked with verbal memory performances in patients with 
MCI but not in those with AD, suggesting the involve-
ment of factors other than neuropsychological ones in 
AD. Thus, neuropsychiatric dimensions commonly pres-
ent in patients with AD should be investigated along with 
anosognosia.57
Frontotemporal dementia
In 1998, Neary and colleagues68 established diagnostic 
criteria for frontotemporal lobar degeneration (FTLD) and 
defined three major subtypes: FTD, semantic dementia (SD), 
and progressive non-fluent aphasia.
Spectrum manifestations of FTLD include two principal 
presentations: gradual behavioral impairment and language 
dysfunction pattern.
DSM-5 classification describes this entity as fronto-
temporal neurocognitive disorder with a behavioral or a 
language variant (‘Behavioral Variant of Frontotemporal 
Neurocognitive Disorder’ [bv-FTD], ‘Language Variant of 
Frontotemporal Neurocognitive Disorder’).
FTLD is a degenerative disorder associated with presen-
tation in younger patients,69 and high prevalence of affected 
relatives (40% of positive family history).49
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NPS in behavioral variant  
of frontotemporal dementia: 
neuroanatomical correlations
bv-FTD begins with atrophy of the orbitofrontal, anterior 
cingulated, and anterior insular cortex and quickly involves 
the basal ganglia.70 Clinically, bv-FTD is characterized by a 
cluster of behavioral symptoms in association with execu-
tive dysfunction. Changes in personality and social behavior 
that include apathy and disinhibition can occur. Patients lose 
their initiative, set aside their personal responsibilities, and 
experience impairment of their professional activities. They 
lose empathy for others and are not interested in what may 
occur in their environment. Patients are not aware of their 
changes in behavior (anosognosia).71,72
Disinhibition presents as inappropriate social behavior, 
loss of decorum, and inappropriate vocabulary. Other clinical 
features include lack of insight, denial of illness, dramatic 
changes in personal hygiene and dressing, repetitive motor 
acts, modifications in eating habits, hyperorality, and hyper-
sexuality; Klüver-Bucy syndrome can even develop.71,72 
These patients can have affective disorders, gluttony, hyper-
metamorphosis, and visual and auditory agnosia.
In FTD subjects, apathy has been associated with atro-
phy in the anterior cingulated cortex, right dorso-lateral 
prefrontal cortex, and adjacent medial frontal cortex. This 
suggests that dysfunction in the frontosubcortical cingulate 
pathways is implicated in apathy regardless of the subtype 
of dementia.11
Patients can develop depression, with exaggerated or 
unmotivated emotional lability, but with an absolute indif-
ference to their surroundings. Anxiety, suicidal ideation, 
amimia, and hypochondriac behavior can occur.73
Patients with bv-FTD exhibit impairment in their self-
criticism, self-perception, and social skills. Clinically, they 
are socially uninhibited and lack emotional recognition and 
empathy. They fail in the recognition of social behavior, and 
are not able to appropriately evaluate the severity of moral and 
social transgressions. In relation to social functioning, labora-
tory tests indicate that physiological and behavioral responses 
are intact in certain emotional contexts. For example, they do 
not differ from control groups in their emotional response to 
loud noises, or to films and scenes with sadness, happiness, 
or fear. Therefore, evidence exists that the physiological and 
behavioral infrastructure that is necessary for some aspects 
and responses to simple emotions is preserved in early stages 
of bv-FTD.73 However, FTD emotional impairment clearly 
occurs in areas of socio-emotional functioning that require 
high-order processing of the social world.
Patients with bv-FTD have deficits in the recognition of 
negative emotions in other people, and in activating more 
complex emotions such as feeling ashamed. Feeling ashamed 
is a member of the ‘self-conscious’ family of emotions; 
others are guilt, pride, and embarrassment. All of them are 
cognitively complex and require an appreciation of the person 
and its social context. It is believed that these self-conscious 
emotions emerge relatively late in the phylogeny and ontog-
eny, and are related to different cerebral regions (for example, 
medial prefrontal cortex, anterior cingular, and insula) that 
are vulnerable in FTD. Feeling ashamed occurs when a per-
son’s behavior infringes social norms. The emotional result 
indicates that a social transgression has occurred and helps 
to motivate attempts to correct and repair the situation.73
In bv-FTD, the estimated prevalence of delusions is 
0%–23%.74,75 Omar et al76 found that patients with bv-FTD 
presented with delusions in an early stage of the disease, 
occurring as an important symptom found in the first year 
since the beginning of the disease. In some patients, delusions 
appeared before cognitive impairment.
NPS in semantic dementia and non-fluent 
aphasia: neuroanatomical correlations
Presentations with language dysfunction are less frequent 
than bv-FTD. Two subtypes are recognized: SD and non-
fluent progressive aphasia (NFA). SD, also known as a 
temporal variant of FTD, begins with asymmetric atrophy of 
the anterior temporal lobes and anterior insulae,77 with later 
involvement of the orbitofrontal cortex and basal ganglia.78 
Clinical features of SD include speech that is fluent but 
poor; the meaning of words is notably altered and anomalies 
are present. NFA patients show agrammatism and effortful 
speech, and single-word comprehension and meanings are 
sparse.79
Behavioral symptoms, particularly depression, anxiety, 
and apathy, are present in SD and NFA.80,81 Rosen et al81 found 
characteristic disinhibition, aberrant motor behavior, and 
eating disorders in patients with a diagnosis of SD.
NPS management
The evaluation of a patient with NPS and cognitive impair-
ment should begin with a complete history of cognitive and 
functional status, co-morbidities, family history, prescribed 
and non-prescribed medications, sleep patterns, and con-
cerns regarding social and environmental changes. Detailed 
neuropsychiatric and medical examinations should be 
conducted to evaluate concomitant or triggering clinical 
intercurrences.
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Table 3 Recent pharmacological research on neuropsychiatric symptom management (2012)
Study Patients Objective Conclusions
Azermai et al96 40 To study the effects of abrupt antipsychotic  
discontinuation in cognitively impaired older  
persons
Abrupt antipsychotic discontinuation appears  
to be feasible in older individuals with BPSD 
Systematically performed discontinuation efforts  
in clinical practice are needed to differentiate  
between patients where antipsychotics have  
no added value and patients where the benefits  
outweigh the risks of their use
Mori et al97 140 To investigate the effects of a cholinesterase  
inhibitor, donepezil, in patients with DLB  
in a randomized, double-blind, placebo- 
controlled exploratory phase ii trial
Donepezil at 5 and 10 mg/day produces significant 
cognitive, behavioral, and global improvements  
that last at least 12 weeks in DLB patients,  
reducing caregiver burden at the highest dose.  
Donepezil is safe and well tolerated
Dominguez-Alonzo  
et al98
Adult rats To explore whether melatonin stimulates  
dendrite formation and complexity in the  
adult rat hippocampus in organotypic slice  
cultures, which is a model that preserves  
the hippocampal circuitry and their  
tridimensional organizations of connectivity
evidence strongly suggests that melatonin may  
be useful in the treatment of neuropsychiatric  
diseases to repair the loss of dendrites and  
re-establish lost synaptic connections
Li et al99 84 To evaluate the efficacy and safety of  
donepezil plus natural hirudin in patients  
with mild-to-moderate AD
Compared with the donepezil treatment in the  
patients with mild-to-moderate AD, the results  
suggest that donepezil combined with natural  
hirudin may improve the treatment effects in  
the ADL, BPSD, and cognition of the patients.  
Furthermore, this joint treatment is safe
Bidzan et al100 71 To determine the effect of pharmacological  
treatment of aggressive behavior, while  
taking into account the dynamics of  
disease progression during observation
Acetylcholinesterase inhibitors may have  
beneficial effects on aggressive behavior in the  
course of AD, similar to that seen with the use  
of valproic acid and antipsychotics
Chatterjee et al101 To evaluate the risk of cerebrovascular  
events associated with use of risperidone,  
olanzapine, and quetiapine in community-  
dwelling older adults in the USA
The study suggested that quetiapine use may  
be associated with a moderately lower risk of  
cerebrovascular events than olanzapine in older  
adults. Prescribers should closely monitor the  
patients treated with atypical agents for the  
incidence of cerebrovascular adverse events
Gardette et al102 534 To determine the all-cause mortality risk  
associated with antipsychotic use among  
AD patients
Antipsychotic use may be associated with an  
increased risk of mortality, but to a lesser extent  
than several other factors that were found to  
be significant predictors of mortality (age, male  
gender, cognitive score, recent hospitalization,  
medical aid). To date, antipsychotic risks  
outweigh their benefits in BPSD for which non- 
pharmacological approaches remain the first-line  
strategy and should be privileged
Abbreviations: AD, Alzheimer’s disease; ADL, activities of daily living; BPSD, behavioral and psychological symptoms; DLB, dementia with Lewy bodies.
Standard laboratory studies and structural (computerized 
axial tomography [CAT] scan, magnetic resonance imaging 
[MRI]) or functional (single photon emission computed 
tomography [SPECT], PET) images of the brain could be 
necessary. New technologies based on neuroimaging (such 
as intracerebral amyloid molecular imaging with PET) and 
biochemical analyses of cerebrospinal fluid (such as mea-
surement of amyloid-beta peptide and hyperphosphorylated 
tau protein), may reveal correlates between intracerebral 
pathology and pre-dementia symptoms.
Information from family members and caregivers is 
important in the presence of both cognitive and behavioral 
impairment, in patients with pre-dementia and dementia 
stages of AD, and FTD. Anxiety, irritability, and agitation in 
patients with dementia can be relieved with environmental 
modifications (avoidance of dark and noisy environments), 
recreation, and music and light therapies.
A wide variety of pharmacologic agents are used in the 
management of psychiatric and behavioral symptoms in 
dementia; for example, cholinesterase inhibitors, N-methyl-
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D-aspartate (NMDA) antagonists, antipsychotics, antidepres-
sants, and other drugs (benzodiazepines, mood stabilizers, 
non-benzodiazepine hypnotics). Despite this, pharmacologic 
therapies are not particularly effective.
A systematic review found that the atypical antipsychotics 
risperidone and olanzapine currently have the best evidence 
for efficacy. However, care is needed to avoid the side effects 
associated with these drugs.82
Each pharmacologic or non-pharmacologic intervention 
should be tailored to the specific symptoms of an indi-
vidual patient, and decisions about the type and duration of 
treatment should be based on its efficacy and the patient’s 
tolerance.
Pharmacological treatment of NPS
Specif ic considerations about each symptom and its 
 pharmacological treatment are outside the scope of this 
review, and previous publications have covered this 
issue.36,83,84 However, Table 3 summarizes some reports from 
the last year on pharmacotherapy of NPS in AD and FTD.
Pharmacotherapy of NPS in Alzheimer’s disease
Pharmacotherapy of NPS in AD has been studied in  numerous 
randomized and controlled trials. The largest number of 
 studies has focused on antipsychotics. Data are of  reasonably 
high quality and indicate that risperidone and  olanzapine are 
more effective than placebo for  institutionalized patients with 
severe agitation, aggression, and psychosis. The efficacy 
of antipsychotics is counterbalanced by safety concerns 
that include cerebrovascular adverse events and mortality. 
Cholinesterase inhibitors and NMDA antagonists appear to 
have modest benefits for patients with mild to moderate–
severe symptoms. Antidepressants are effective for treating 
depression in AD, but more data are required to determine 
the efficacy of trazodone and citalopram for agitation and 
 aggression. Carbamazepine appears to be  efficacious, 
although side effects and concerns about drug–drug inter-
actions limit its use. The data do not support the use of 
valproate. Benzodiazepines should only be considered for 
short-term, as-needed use. Data regarding other pharmaco-
logic interventions, such as beta blockers, buspirone, and 
estrogen preparations, are insufficient.85
Pharmacotherapy of NPS in frontotemporal 
dementia
To date, there are no approved and established pharmacologic 
treatment options for FTD. Available treatment strategies are 
based mainly on small clinical trials, miscellaneous case 
reports, or small case-controlled studies. The results of these 
studies, and conclusions about the efficacy of the medications 
used are often contradictory. Approved therapeutic agents 
for AD, such as acetylcholinesterase inhibitors and NMDA 
antagonists, have been used off-label to treat cognitive and 
behavioral symptoms in FTD, but outcomes have not been 
consistent. For behavioral or psychopathological symptoms, 
treatment with antidepressants, especially selective serotonin 
reuptake inhibitors, could be helpful. Antipsychotics are often 
not well tolerated because of their adverse effects; these drugs 
should be given very carefully because of an increased risk of 
cerebrovascular events. In addition to pharmacologic options, 
physical, occupational, or speech therapy can be applied to 
improve functional abilities. Currently, no effective treatment 
is available that targets the cause of FTD.86
Conclusion
It has already been demonstrated that the presence of NPS 
in MCI patients is an indicator of increased risk of progres-
sion to dementia. However, the topic is vast, since doctors 
have only very recently begun to recognize the existence of 
patients with behavioral disorders without cognitive impair-
ment as another population at risk of developing degenera-
tive dementia. Therefore, the focus has been placed on the 
need to learn about these NPS in pre-dementia stages of 
AD and FTD.
Psychiatric and behavioral symptoms are present univer-
sally in patients with dementia. Diagnosis, characterization, 
and management are essential in clinical practice in order 
to ameliorate caregiver burden as well as to avoid frequent 
hospitalizations and early institutionalization.
Pharmacologic and non-pharmacologic interventions 
should be tailored to the specific symptoms of each individual 
patient, and decisions about the type and duration of treatments 
should be based on their efficacy and patients’ tolerance.
A multidisciplinary health team is fundamental to the 
optimal management of patients with NPS and cognitive 
impairment.
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